COVAX — Stock Film

Stock Expert AI presents

COVAX

Columbia Small Cap Value and Inflection Fund;A

~2 min film100% real numbers0 jargon

WHAT DOES THIS COMPANY DO?

Columbia Small Cap Value and Inflection Fund;A. A quick introduction.

On the stock market since 2002, it operates in the world of money and finance. Now — the numbers.

on the stock market since 2002
$904.6M market value

THE FIVE-YEAR JOURNEY

Below the peak, but no collapse.

The stock trades 33% below its peak. The market has trimmed its expectations for the company.

1

THE BRIGHT SIDE · 1/1

Pays a steady dividend

It pays out $2.34 per share each year — regular cash for whoever holds the stock.

1

THE RISKS · 1/1

A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 17/100.

FINALE · THE GRADE

C

0 / 100 · MoonshotScore

On our five-subject report card, COVAX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: COVAX is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?

Open the stock page →

This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film